XML 32 R9.htm IDEA: XBRL DOCUMENT v3.20.2
CASH EQUIVALENTS AND MARKETABLE SECURITIES
 6 Months Ended
Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
CASH EQUIVALENTS AND MARKETABLE SECURITIES CASH EQUIVALENTS AND MARKETABLE SECURITIES
Cash Equivalents and Marketable Securities
The table below summarizes the Company’s cash equivalents and marketable securities (in thousands):
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
(Losses)		Estimated
Fair Value
June 30, 2020
Assets
Cash equivalents:
Money market funds$116,393  $—  $—  $116,393  
Total116,393  —  —  116,393  
Marketable securities:
Commercial paper securities89,796  383  —  90,179  
Corporate debt securities81,424  420  —  81,844  
U.S. government-sponsored entity debt securities25,211  176  —  25,387  
Total196,431  979  —  197,410  
Total cash equivalents and marketable securities$312,824  $979  $—  $313,803  
December 31, 2019
Assets
Cash equivalents:
Money market funds$30,496  $—  $—  $30,496  
Commercial paper securities2,998  1  —  2,999  
Total33,494  1  —  33,495  
Marketable securities:
Commercial paper securities155,230  145  (7) 155,368  
Corporate debt securities94,905  115  (3) 95,017  
U.S. government-sponsored entity debt securities53,411  91  (9) 53,493  
Total303,546  351  (19) 303,878  
Total cash equivalents and marketable securities$337,040  $352  $(19) $337,373  
The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):
June 30,
2020		December 31,
2019
Maturing in one year or less$197,410  $282,046  
Maturing after one year through five years—  21,832  
Total$197,410  $303,878  

The Company had no realized losses of its available-for-sale securities for the three and six months ended June 30, 2020 or 2019. The Company periodically reviews the available-for-sale investments for other-than-temporary impairment losses. No investments were other-than-temporarily impaired at either June 30, 2020 or December 31, 2019. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For available-for-sale securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company's review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company's ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these securities at June 30, 2020. All available-for-sale securities with unrealized losses have been in a loss position for less than 12 months.